Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 6/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1973791 | 0.77 | RAB9A (0.52) | HTTHTR2ARAB9ANPC1TDP1 | |
| SCHEMBL26134353 | 0.77 | ALKBH1 (0.36) | HDAC9POLBL3MBTL1SMN1; SMN2HSD17B10 | |
| SCHEMBL1975432 | 0.77 | HTR2A (0.40) | HTTFAAHHTR2ARAB9ANPC1 | |
| SCHEMBL29805613 | 0.75 | PDE10A (0.38) | HDAC9MGLL | |
| SCHEMBL31429322 | 0.75 | PTGIR (0.41) | FAAHHDAC9RAB9AL3MBTL1 | |
| SCHEMBL19207006 | 0.74 | AURKA (0.38) | HDAC9RAB9AKDM4EL3MBTL1MAPT | |
| SCHEMBL25679963 | 0.72 | CSF1R (0.32) | L3MBTL1 | |
| SCHEMBL18555068 | 0.72 | CTSD (0.34) | — | |
| SCHEMBL31617088 | 0.71 | HDAC9 (0.36) | HDAC9MGLLL3MBTL1 | |
| Dimethylformamide SCHEMBL27895442 | 0.71 | ADORA3 (0.32) | HDAC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3186224-B1 | SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS | HOFFMANN LA ROCHE (CH) | 2021-04-21 | — | — | EP | disclosed |
| CN-107001259-B | Substituted azetidine derivatives as TAAR ligands | 豪夫迈·罗氏有限公司 | 2019-12-06 | — | — | CN | disclosed |
| US-10023559-B2 | Substituted azetidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2018-07-17 | — | — | US | disclosed |
| CN-107001259-A | Substituted azetidine derivatives as TAAR ligands | 豪夫迈·罗氏有限公司 | 2017-08-01 | — | — | CN | disclosed |
| EP-3186224-A1 | SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS | F. Hoffmann-La Roche AG (CH) | 2017-07-05 | — | — | EP | disclosed |
| US-20170144994-A1 | SUBSTITUTED AZETIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2016030310-A1 | SUBSTITUTED AZETIDINE DERIVATIVES AS TAAR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-03-03 | — | — | WO | disclosed |
| EP-2566855-B1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-05-21 | — | — | EP | disclosed |
| US-8673894-B2 | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20140045820-A1 | 2,5,6,7-Tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-02-13 | — | — | US | disclosed |
| EP-2566855-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2013-03-13 | — | — | EP | disclosed |
| US-8389513-B2 | 2-amino-5,5-difluoro-5,6-dihydro-4H-[1,3]oxazin-4-yl)-phenyl]-amides | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| EP-2509965-A1 | 2-AMINO-5, 5-DIFLUORO-5, 6-DIHYDRO-4H-OXAZINES AS BACE 1 AND/OR BACE 2 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-20110312937-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | SIENA BIOTECH S.P.A. (IT) | 2011-12-22 | — | — | US | disclosed |
| WO-2011138293-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-11-10 | — | — | WO | disclosed |
| US-20110144097-A1 | 2-AMINO-5,5-DIFLUORO-5,6-DIHYDRO-4H-[1,3]OXAZIN-4-YL)-PHENYL]-AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | US | disclosed |
| WO-2011069934-A1 | 2-AMINO-5, 5-DIFLUORO-5, 6-DIHYDRO-4H-OXAZINES AS BACE 1 AND/OR BACE 2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045820-A1 | 2,5,6,7-Tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds | BACE2, BACE1, PSEN2 | HTT 1542/4885FAAH 697/4885HTR2A 235/4885 |
| US-10023559-B2 | Substituted azetidine derivatives | HTR1B, MTNR1B, DRD2 | HTT 591/4885FAAH 989/4885HTR2A 7/4885 |
| US-20170144994-A1 | SUBSTITUTED AZETIDINE DERIVATIVES | HTR1B, MTNR1B, DRD2 | HTT 591/4885FAAH 989/4885HTR2A 7/4885 |
| US-20110312937-A1 | 2,5,6,7-TETRAHYDRO-[1,4]OXAZEPIN-3-YLAMINE OR 2,3,6,7-TETRAHYDRO-[1,4]OXAZEPIN-5-YLAMINE COMPOUNDS | BACE2, BACE1, PSEN2 | HTT 1542/4885FAAH 697/4885HTR2A 235/4885 |
| US-20110144097-A1 | 2-AMINO-5,5-DIFLUORO-5,6-DIHYDRO-4H-[1,3]OXAZIN-4-YL)-PHENYL]-AMIDES | BACE2, BACE1, APP | HTT 953/4885FAAH 667/4885HTR2A 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.